METAVIA INC. Debt Conversion, Converted Instrument, Amount
METAVIA INC. (MTVA) reported Debt Conversion, Converted Instrument, Amount of $548.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-04-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2021-04-15
- METAVIA INC. debt conversion, converted instrument, amount for fiscal 2019 was $548.00K, a 179.59% increase from fiscal 2018.
- METAVIA INC. debt conversion, converted instrument, amount for fiscal 2018 was $196.00K.
| Period end | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|
| 2019-12-31 | $548.00K 10-K · filed 2021-04-15 | |
| 2018-12-31 | $196.00K 10-K · filed 2019-03-18 | |
| 2015-06-30 | $2.78M 10-Q · filed 2016-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |